Health Care • Medical/Dental Instruments
$10.24 ▲ +0.20
(+1.99%)
MKT CAP: $417.1M • VOL: 399.3K
52W L $9 52W H $17
OFIX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $822.3M | $799.5M | $746.6M |
| YoY Revenue Growth % | +2.9% | +7.1% | — |
| Gross Profit | $566.0M | $545.9M | — |
| Gross Margin % | 68.8% | 68.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$81.4M | -$84.6M | -$139.1M |
| Operating Margin % | -9.9% | -10.6% | -18.6% |
| Net Income (GAAP) | -$92.2M | -$126.0M | -$151.4M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $33.3M | $25.8M | -$45.8M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | $33.3M | $25.8M | -$45.8M |
| FCF Margin % | 4.1% | 3.2% | -6.1% |
| Return on Invested Capital (ROIC %) | -12.2% | -11.6% | — |
| Cash & Short-Term Equivalents | $82.0M | $83.2M | — |
| Total Debt (Short + Long Term) | $157.4M | $157.0M | — |
| Total Stockholders' Equity | $450.0M | $503.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR OFIX.